Novel type 2 diabetes prediction score based on traditional risk factors and circulating metabolites: Model derivation and validation in two large cohort studies

Ruijie Xie,Christian Herder,Sha Sha,Lei Peng,Hermann Brenner,Ben Schoettker
DOI: https://doi.org/10.1101/2024.06.12.24308860
2024-06-13
Abstract:Importance. The predictive value of metabolomics quantified by nuclear magnetic resonance (NMR) for type 2 diabetes risk has not been assessed before. In addition, previous studies with other metabolomics quantification methods did not have an external validation cohort, which leaves doubts about the robustness of the derived models in other settings. Objective. This project aimed to evaluate the incremental predictive value of metabolomic biomarkers for assessing the 10-year risk of type 2 diabetes when added to the clinical Cambridge Diabetes Risk Score (CDRS), which includes HbA1c. Design, Setting, and Participants. We utilized 60,362 participants of the UK Biobank (UKB) for model derivation, 25,870 participants of the UKB for internal validation and 4,383 participants from the German ESTHER cohort for external validation. Exposures. A total of 249 NMR-derived metabolites were quantified using nuclear magnetic resonance (NMR) spectroscopy. Main Outcomes and Measures. The main outcome was 10-year type 2 diabetes incidence. Results. Eleven metabolomic biomarkers, including glycolysis-related metabolites, ketone bodies, amino acids, and lipids, were selected with LASSO regression. In internal validation within the UKB, adding these metabolites Harrel's C-index of the clinical CDRS from 0.815 to 0.834 (P<0.001) and the continuous net reclassification index (NRI) was 39.8% (P<0.001). External validation in the ESTHER cohort showed a comparable C-index increase from 0.770 to 0.798 (P<0.001) and a continuous NRI of 33.8% (P<0.001). Conclusions and Relevance. Adding 11 biomarkers, mainly from glucose and lipid metabolism, to the clinical CDRS led to a novel type 2 diabetes prediction model, the UK Biobank Diabetes Risk Score (UKB-DRS), which substantially outperformed the clinical CDRS. As only very limited clinical information and a blood sample are needed for the UKB-DRS, and as high-throughput NMR metabolomics are becoming increasingly available at low costs, this model has considerable potential for routine clinical application in diabetes risk assessment.
Epidemiology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is: whether the accuracy of predicting type 2 diabetes risk can be improved by adding metabolites measured by nuclear magnetic resonance (NMR) spectroscopy in blood samples to the clinical Cambridge Diabetes Risk Score (CDRS). Specifically, the researchers hope to evaluate the incremental value of metabolomic markers in predicting the risk of developing type 2 diabetes within 10 years, especially whether these markers can significantly enhance the predictive performance of the existing CDRS model. CDRS is already a good predictive model that includes HbA1c, a major diabetes risk indicator, but the researchers hope to further improve its predictive ability by adding new metabolite markers. To achieve this goal, the research team used data from the UK Biobank and the German ESTHER cohort to conduct model derivation and validation. Through this method, they hope to develop a more accurate type 2 diabetes prediction model, so as to identify high - risk individuals earlier and guide clinicians and high - risk populations to choose preventive measures.